FDA has approved gefurulimab (Klygefa), developed by Alexion, AstraZeneca Rare Disease, for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, AstraZeneca announced on November 16, 2026.¹ Gefurulimab is a dual-binding nanobody complement C5 inhibitor that patients inject themselves under the skin once a week with an autoinjector. The approval was based on the pivotal phase 3 PREVAIL trial.¹
Key facts
- Drug: gefurulimab (Klygefa; Alexion, AstraZeneca Rare Disease)
- Class: Dual-binding nanobody complement C5 inhibitor (also binds albumin)
- Indication: Adults with AChR antibody-positive generalized myasthenia gravis
- Administration: Once-weekly subcutaneous self-injection via autoinjector
- Trial: PREVAIL (NCT05556096); phase 3, randomized, placebo-controlled, n=260
- Primary end point met: MG-ADL difference -1.6 vs placebo at week 26 (p<.0001)
- Onset: Clinical improvement as early as week 1
- Safety: Most common TEAEs were injection site reactions, back pain, and vomiting
- Approval: FDA (US), announced November 16, 2026
- Other approvals: EU, Japan, and other countries; China under review
“With this approval, patients in the US gain a targeted treatment option that empowers greater autonomy with the established efficacy of C5 complement inhibition,” said Kelly Gwathmey, MD, associate professor of neurology at Columbia University Vagelos College of Physicians and Surgeons and a principal investigator in the trial at Virginia Commonwealth University, in a company press release.¹
What did the PREVAIL trial show?
PREVAIL (NCT05556096) enrolled 260 adults with AChR antibody-positive gMG from 20 countries, randomized 1:1 to gefurulimab or placebo for 26 weeks.¹,² Patients received a weight-based loading dose on day 1, followed by weekly weight-based maintenance doses starting on day 8.¹
Gefurulimab met the primary end point, improving the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score from baseline at week 26 vs placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p<.0001). Clinical improvement was seen as early as week 1.¹
In the published trial results, the Quantitative Myasthenia Gravis (QMG) score improved by 4.5 points with gefurulimab vs 2.4 points with placebo (difference: -2.1 [95% CI: -3.1, -1.1], p<.001). An MG-ADL reduction of at least 3 points was reached by 65.6% of patients on gefurulimab vs 52.1% on placebo.³ Rescue therapy was used by 5.3% of gefurulimab-treated patients and 12.4% of placebo-treated patients.³
What was the safety profile?
Gefurulimab was generally well tolerated, and its safety profile was consistent with previous gMG trials of the C5 inhibitors eculizumab and ravulizumab.¹ Rates of treatment-emergent adverse events (TEAEs) were similar between the gefurulimab and placebo groups, and most were grade 1 or 2.¹ The most common TEAEs with gefurulimab were injection site reactions (12%), back pain (8%), and vomiting (5%).¹
How does gefurulimab work?
Gefurulimab binds the C5 protein in the terminal complement cascade. When that cascade is activated in an uncontrolled way, the immune system attacks healthy cells.¹ In AChR antibody-positive gMG, antibodies that bind receptors at the neuromuscular junction activate complement, causing inflammation and disrupting communication between nerves and muscles.¹ The nanobody also binds serum albumin, which extends its half-life and allows once-weekly dosing.¹